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Abstract: Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis 
(MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently 
investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral 
cladribine have recently been published. However, benefits need to be weighed against the risks 
to define the role of these compounds within current treatment regimens. In this review, data on 
the efficacy of a promising compound, oral cladribine, are discussed and balanced with known 
and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place 
of this drug in treatment algorithms for MS in the future.
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Introduction
Multiple sclerosis (MS) is a chronic and debilitating immune-mediated disease of the 
central nervous system (CNS). MS is not a homogeneous disease entity and therefore, 
as new therapeutics emerge, will require individual therapy regimens in the future. 
As a chronic, so far not curable disease, therapy is required for an indefinite – if not 
life long – period of time. In current concepts of MS treatment, drugs that influence 
immunological reactions are used to alter the course of this disorder and to finally 
reduce the grade of disability. MS, most relevant for the development of new treatment 
options, is a disease of low mortality in a young population and treatment primarily 
seems to be effective in the early inflammatory state of disease when patients suffer 
only from a low grade of impairment. In addition, no definite surrogate parameters exist 
to predict the individual course of disease in its early stages, and the individual grade 
of disability in the future cannot be anticipated with certainty. Thus, ideal   treatment 
of MS would fulfill the following general criteria:
–  maximal efficacy (ideal: cure)
–  minimal adverse effects (ideal: none)
–  maximal compliance (ideal: 100%)
–  easy dosing regimes.
Currently available first-line therapeutics are characterized by their favorable and 
well-defined safety profile. Since the early 1990s, these disease-modifying drugs 
(DMD) have been implemented as treatments for MS. Ever since, interferon beta 
(IFNβ) or glatiramer acetate (GA) has become the standard of care for relapsing-
remitting MS (RRMS).1 Different formulations of IFNβ are available, including 
IFNβ-1a for weekly intramuscular (IM) or 3 times weekly subcutaneous (SC) Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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administration, or IFNβ-1b SC every other day. GA is a 
synthetic oligopeptide and requires daily administration. 
In randomized controlled phase 3 trials, all of these agents 
showed to be superior to placebo regarding clinical end 
points.2–15 Recently published comparative trials did not 
provide evidence for superiority of one or the other first-line 
DMD.16–18 In addition, data on comparative paraclinicial 
efficacy is controversial,12,15,19–24 and a possible tendency 
towards a slight advantage on magnetic resonance imaging 
(MRI) criteria for IFNβ compared with GA goes along with 
slightly unfavorable tolerability rates (mainly higher rate 
of flulike symptoms). Thus, individual decision for one or 
the other agent is currently based on the preferred route 
of application (SC or IM) and the individual tolerability 
of the agent used. The main advantage of these first-line 
DMD agents for RRMS is their established positive safety 
profile. Main drawbacks of these agents are
–  limited efficacy
–  limited compliance and long-term acceptance by 
patients.
The latter mainly relates to their SC or IM mode of appli-
cation. Local adverse effects at the sites of injection impair 
quality of life and long-term acceptance by patients.25–30
Promising new targets in MS therapy have been defined 
within the last decades and target-specific treatment options 
became available. Some of these treatment options have 
been tested in clinical trials, and have shown very promising 
results regarding efficacy. But, as outlined above, to play 
a role as first-line therapeutics in MS, these drugs need to 
display a reasonable safety profile in patients on long-term 
therapy or even life-long therapy. This matter of risk:benefit 
ratio became strikingly apparent when natalizumab was 
introduced in the therapy for MS. Natalizumab was the first 
drug of rational drug design approved for MS therapy, a 
humanized monoclonal IgG4-antibody, specifically designed 
to target a critical step of leukocyte migration into areas of 
inflammation within the CNS.31,32 Phase 3 clinical trials have 
clearly shown its advantages: high efficacy and high rates 
of compliance by intravenous (IV) monthly infusion.33,34 
However, immediately after the completion of a phase 3 trial 
that led to its approval, safety issues, and most notably the 
risk of progressive multifocal leukoencephalopathy (PML), 
became   apparent.35–37 Restriction of natalizumab to patients 
with highly active MS or patients, not responding to first-line 
treatment, was not congruent with the inclusion criteria of 
these studies but based on risk–benefit considerations. Just 
recently, new cases of PML occurring in patients receiving 
natalizumab monotherapy have been published and the 
long-term safety data might further limit its use in the 
future.38–40 Interestingly, these safety issues are most likely 
not only restricted to natalizumab but also are relevant for 
other currently investigated drugs of this second generation 
of target-specific immunosuppressive monoclonal antibodies. 
One lesson to be learned from natalizumab and other 
  compounds such as rituximab, efalizumab, or alemtuzumab 
in drug development is the awareness that target specificity 
does not guarantee disease-specific efficacy. Although the 
mode of action of these drugs seems to be highly specific, 
their administration to young and otherwise healthy patients 
results in a severe alteration of immunocompetence going 
along with an increased risk of potential life-threatening 
infections (eg, risk of PML in natalizumab, efalizumab,41 
or rituximab)42 or autoimmune (eg, risk of autoimmune 
thrombocytopenia and thyroid disease in alemtuzumab)43 
complications. Thus, the risk–benefit consideration is   crucial 
and, although low, the risk of a potential life-threatening 
complication in MS population demands a critical patient 
selection and high standards of safety surveillance plans.
This is also an issue of concern in the development of 
new oral drugs for MS treatment. Easy dosing regimens and 
a convenient mode of administration are the most   relevant 
  advantages of this group of drugs. For these   reasons, approval 
of an oral drug would be highly   appreciated by patients improv-
ing quality of life and increasing   adherence to therapy.44,45 
Among 5 oral therapies currently in phase 3 clinical trials 
(fingolimod, laquinimod, fumeric acetate,   teriflunomide, 
and oral cladribine; Table 1), fingolimod and oral cladribine 
have already completed phase 3 clinical trials that were just 
recently published.46–49 In this review, data on efficacy of a 
promising compound, oral cladribine, are contrasted with 
known and potential risks. As the manufacturer already 
applied to the US Food and Drug administration and Europe, 
the Middle East and Africa for approval, risks and benefits 
of this drug need to be discussed to define the potential role 
within established treatment concepts.
Cladribine and its mode of action
Carson et al50,51 discovered that the lymphopenia observed in 
an inherited disorder of adenosine deaminase   deficiency was 
caused by the accumulation of deoxyadenosine   nucleotides 
within lymphocytes. Based on this observation, this group 
started to synthesize therapeutic purine nucleoside ana-
logs, including cladribine (2-chlorodeoxyadenosine), to 
preferentially target lymphocytes.50,51 Cladribine is a prod-
rug   requiring intracellular phosphorylation to become an 
active purine nucleoside analog. The prodrug is   resistant Drug Design, Development and Therapy 2010:4
Table 1 Oral drugs in clinical development for multiple sclerosis
Drug Phase 3 (indication,  
comparator)
Phase 2 (primary 
end point)
Safety profile (most relevant data  
from recent clinical experience)
Cladribine (1) CIS, placebo 
(2) RRMS, placebo46 
(3) RRMS, add-on to IFNβ
Not performed for 
oral formulation
Lymphocytopenia, exacerbation of herpes 
virus infection, one case of tuberculosis 
excerbation, single cases of malignancies 
(melanoma, pancreas carcinoma, and  
ovarian carcinoma)
Fingolimod (1) RRMS, placebo47 
(2) RRMS, placebo 
(3) RRMS, IFNβ48  
(4) PPMS
MRi80 (median total 
number of gadolinium- 
enhanced lesions on 
MRi): 1.25 mg or 5 mg 
or placebo: 1 
(P = 0.001) or 3 lesions 
(P = 0.006) or 5 lesions
Lymphocytopenia, exacerbation of herpes 
virus infection (2 fatal cases), macula edema, 
cardiovascular side effects
Teriflunomide (1) CIS, placebo 
(2) RRMS, placebo 
(3) RRMS, IFNβ
MRi81 (mean number of 
CU active lesions per 
scan): 7 or 14 mg/day: 
reduction by 61%
GI symptoms, hepatotoxicity, low risk of 
pancytopenia, low risk of endogenous 
infections, teratogenicity
Laquinimod (1) RRMS, placebo 
(2) RRMS, IFNβ
MRi82 (cumulative 
number of active 
lesions over 24 wk): 
reduction by 44%
Iritis and burning sensation; during follow-up 
acute tonsillitis, one case of breast cancer
BG12 (1) RRMS, placebo 
(2) RRMS, glatiramer acetate
MRi83 (total number of 
new gadolinium- 
enhancing lesions on 
MRi week 12 to 24): 
reduction by 69%
Abdominal pain, flushing, hot flush,  
headache, and fatigue
Abbreviations: CIS, clinically isolated syndrome; CU, combined unique; RRMS, relapsing-remitting multiple sclerosis; MRI, magnetic resonance imaging; PPMS, primary 
progressive multiple sclerosis; IFNβ, interferon beta.
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to degradation by adenosine desaminase and is able to 
enter cells via purine nucleoside transporters.52 Once 
within the cell, cladribine undergoes initial phosphoryla-
tion by deoxycytidine kinase (DCK) to finally become the 
active 2-chlorodeoxyadenosinetriposphate.53 To inactivate 
cladribine-triphosphate nucleotides and to prevent intracel-
lular accumulation, dephosphorylation by 5′-nucleotidase 
(5′-NTase) is required.   Compared with other cell types, 
resting and activated   lymphocytes have high levels of DCK 
but low levels of 5′-NTase. Thus, cladribine becomes particu-
larly activated to its active form within lymphocytes making 
these cell types preferentially vulnerable to its effects.54 The 
accumulation of cladribine nucleotides leads to breaks in 
DNA strands,   interferes with DNA synthesis and repair, and 
ultimately results in a sustained reduction of lymphocyte 
counts.55 Therefore, the main immunosuppressive effect of 
cladribine is mediated via immune cell depletion, of both 
the proliferating and the quiescent lymphocytes.50 At doses 
used in clinical trials for MS, cladribine differentially affects 
CD4+, CD8+, and CD19+ lymphocyte subpopulations, pos-
sibly related to differences in the DCK/5′-NTase-ratio.56,57 
CD4+ T cells are preferentially reduced compared with CD8+ 
T cells, resulting in a lower CD4/CD8 ratio, affecting both 
naive and memory T cells. Although CD19+ B-cell reduction 
occurs rapidly, recovery from the nadir is seen earlier and 
more pronounced compared with T cells.56–60 Recent evidence 
indicates that cladribine may also impede the influx of T cells 
into the CNS, and might also influence levels of soluble adhe-
sion   molecular levels such as sICAM or sE-Selectin.61,62 In 
  addition,   cladribine may exert immunomodulatory effects 
on   proinflammatory cytokine profiles: Mean values of 
Interleukin-2 (IL-2) and soluble interleukin-2 receptor levels 
measured 12 months after cladribine treatment for chronic 
progressive MS were found to be lowered.63 IL-8-levels were 
decreased in   cerebrospinal fluid (CSF) of cladribine-treated 
RRMS patients, whereas CCL-5 levels were decreased both 
in CSF and serum.64 These and other data suggests that 
  cladribine not only has an leukocyte depleting effect, but also 
may exert a direct effect on effectors T-cell function.59,65
Pharmacokinetics of cladribine
Cladribine is rapidly absorbed and its oral bioavailability 
varies between 37% and 51%.53 The terminal half-life varies 
from 5.7 to 19.7 hours. In CSF, the concentration has been Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
120
Warnke et al
reported to be approximately 25% of that in plasma in patients 
without CNS disease, indicating the ability of cladribine 
to cross the blood–brain barrier. The renal clearance of 
cladribine is about 51% of total clearance and 21%–35% 
of an IV-administered dose is excreted un-metabolized in 
the urine.53
Efficacy of cladribine in clinical trials
Efficacy data with parenteral cladribine
Cladribine has been primarily used for reduction of   aberrant 
lymphocyte populations in a variety of hematological 
disorders, and the parenteral formulation is treatment of 
choice for hairy cell leukemia.66–68 In addition, cladribine 
has been tested in autoimmune disorders such as rheuma-
toid arthritis and systemic lupus erythematodus-associated 
glomerulonephritis.69,70 In MS, parenteral cladribine has 
been evaluated for relapsing or progressive forms. The 
MS-Scripps-trial71 was a 2-year, placebo-controlled, 
double-blind, crossover study started in 1992 to evaluate 
cladribine IV for chronic progressive MS. In the first year, 
patients were given cladribine 0.1 mg/kg/day IV for 7 days 
as 4-monthly courses (total dose, 2.8 mg/kg or placebo). 
During the second year, patients of the first year’s placebo 
group were given 0.10, 0.05, and 0.05 mg/kg/day IV for 
7 consecutive days in 3 successive monthly courses (total 
dose, 1.4 mg/kg). In the Scripps-C-trial,72 an 18-month, 
placebo-controlled, double-blind study in the treatment 
of patients with RRMS, patients received either placebo 
or cladribine 0.07 mg/kg/day SC for 5 consecutive days 
as 6-monthly courses (total cumulative dose, 2.1 mg/kg). 
In the MS-001-trial, safety and efficacy were evaluated in 
patients with progressive MS, assigned to receive placebo 
or cladribine 0.07 mg/kg/day SC for 5 consecutive days 
for every 4 weeks for either 2 or 6 cycles (total dose, 0.7 
or 2.1 mg/kg), followed by placebo for a total of 8 cycles. 
To summarize, efficacy data of these most relevant phase 
2/3 clinical studies in 262 involved patients, parenteral 
cladribine showed positive results in patients with both 
relapsing and progressive forms of MS. A total of 183 
patients received cumulative doses of 0.7–2.8 mg/kg of 
cladribine and individual results were suggestive not only 
for improvement of MRI-criteria (the number and volume 
of T1 gadolinium-enhancing lesions, the accumulation 
of T2 lesion volume), but also for neurological outcome 
measures (relapse rate and disability progression). Based 
on this treatment experience, a regimen for oral cladribine 
was developed and recently investigated in phase 3 clinical 
trial settings.73
Efficacy data with oral cladribine
The clarity trial
Study design
Results of the CLAdRIbine Tablets treating MS orallY 
(CLARITY) Trial, as one of 3 phase 3 clinical trials for 
oral drugs for MS to be completed, have been recently 
published.46 CLARITY was performed in a randomized, 
double-blind, placebo-controlled, multicenter, 96-week 
setting with 3 parallel groups. Patients with RRMS,74 aged 
18–65, who had at least 1 relapse within 12 months before 
study entry, and a score of no more than 5.5 on the Kurtzke 
Expanded Disability Status Scale (EDSS)75 were included. 
Patients with previous immunosuppressive treatment and 
patients with abnormal platelet, neutrophil, or leukocyte 
counts were excluded. In total, between 2005 and 2007, 
1,326 patients were assigned in a 1:1:1 ratio to receive either 
3.5 mg/kg or 5.25 mg/kg or matching placebo. The study 
drug was administered as short courses, each consisting of 
one or two 10-mg   cladribine tablets or matching placebo 
given once daily for the first 4 or 5 days. In the 5.25-mg/kg 
group, patients received 4 courses of cladribine in the first 
48-week treatment period. In the 5.25-mg/kg-group, patients 
received 2 courses of cladribine, followed by 2 courses of 
placebo. Four courses of placebo were administered to the 
placebo group. In all groups, courses were started at day 
1, followed by courses at weeks 5, 9, and 13. In the second 
48-week period, both cladribine groups received 2 courses 
of cladribine, and the placebo group received 2 courses 
of placebo, starting at weeks 48 and 52 (Figure 1). After 
week 24, rescue therapy with IFNβ-1a SC was available for 
patients with more than 1 relapse or a sustained increase in 
the EDSS score.
The primary end point was the rate of relapse at 96 weeks. 
A relapse was defined as an increase of 2 points in at least 1 
functional system of the EDSS or an increase of 1 point in 
at least 2 functional systems in the absence of fever, lasting 
for at least 24 hours and to have been preceded by at least 
30 days of clinical stability or improvement. Secondary 
clinical outcome measures were the proportion of patients 
who were relapse-free, the time to sustained progression of 
disability (time to a sustained increase of at least 1 point in the 
EDSS score or an increase of at least 1.5 points if the base-
line EDSS score was 0), the time to the first relapse, and the 
proportion of patients receiving rescue therapy with IFNβ-1a 
SC. Secondary MRI end points were the mean number of 
lesions per patient per scan at 96 weeks for gadolinium-
enhancing T1-weighted lesions, active T2-weighted lesions, 
and combined unique lesions (new gadolinium-enhancing Drug Design, Development and Therapy 2010:4
Screening
Patients with RRMS
randomization (1:1:1)
(n = 1327)
Placebo
Placebo
Placebo
Clarity study – phase III Extension study
per year Two courses cladribine
Two courses
Four courses (followed
by two courses)
Placebo
Cladribine
per year Two courses cladribine
per year Two courses cladribine
per year Two courses cladribine
Two courses cladribine
in the 2nd year
Four courses cladribine
in the 1st year
Study-
day 1
−4 59 13 48 52
Weeks
Courses
96100 144148
Figure 1 Study design of the CLARITY study.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
121
Cladribine for MS
T1-weighted lesions or new nonenhancing or enlarging 
T2-weighted lesions).
Study results
The annualized relapse rate at 96 weeks was significantly 
reduced in both treatment groups, as compared with 
  placebo (0.14 in the cladribine 3.5-mg group and 0.15 in 
the   cladribine 5.25-mg group vs 0.33 in the placebo group; 
Figure 2). Thus, relative reductions of the annualized relapse 
rate were 57.6% and 54.5%, respectively (P , 0.001). The 
proportion of patients who remained relapse-free at 96 weeks 
was significantly higher in both cladribine groups than in 
placebo (79.7% and 78.9% vs 60.9%; P , 0.001). There 
was a significant relative reduction in the risk of 3-month 
sustained progression of disability in both cladribine groups, 
as compared with placebo (33% reduction for cladribine 
3.5 mg, 31% reduction for cladribine 5.25-mg group) with 
corresponding increase in the odds for remaining free of 
3-month sustained disability progression. Additional clinical 
outcome measures, such as the time to the first relapse or the 
need for rescue therapy with IFNβ-1a SC were also in favor 
for both of the cladribine treatment groups.
Regarding MRI outcome measures, patients in the 
cladribine 3.5-mg group and cladribine 5.25-mg group had 
significant lower mean numbers of lesions per patient per scan 
than those in the placebo group for gadolinium-enhancing 
T1 lesions (0.12 and 0.11 vs 0.91 for placebo), active T2 
lesions (0.38 and 0.33 vs 1.43 for placebo), and combined 
unique lesions (0.43 and 0.38 vs 1.72 for placebo).
Ongoing phase 3 clinical trials
Following completion of the CLARITY study, patients are 
given the opportunity to participate in the 96-week phase 3b 
extension study (ClinicalTrials.gov identifier: NCT00641537; 
Figure 1). Patients originally randomized to placebo will 
receive oral cladribine, whereas those originally randomized 
to cladribine will be rerandomized to either cladribine tablets 
or placebo. This study has been primarily designed to provide 
information on the longer term safety and tolerability of oral 
cladribine administered for an additional third and forth year 
in patients with RRMS, including clinical laboratory testing, 
electrocardiograms, and review of adverse events. Clinical 
efficacy measures are secondary end points to evaluate the 
sustained effects of treatment. Estimated primary completion 
date is September 2011.
The Oral Cladribine Added ON To Rebif New Formulation 
in Patients With Active Relapsing Disease (ONWARD)-trial 
(ClinicalTrials.gov identifier: NCT00436826) is a 96-week, 
randomized, double-blind, placebo-controlled, phase 2b trial 
in patients with active MS. This study evaluates the safety 
and tolerability of oral cladribine compared with placebo as 
an add-on therapy to IFNβ treatments in patients with active 
RRMS or secondary progressive MS with superimposed 
relapses. Clinical end points and MRI criteria are secondary Drug Design, Development and Therapy 2010:4
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Figure 2 Relapse rate reduction as the primary outcome of the CLARITY study.
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outcome measures in this study. Estimated primary comple-
tion date is October 2013.
The Oral Cladribine in Early MS (ORACLE) – trial 
(ClinicalTrials.gov identifier: NCT00725985) is a 96-week 
randomized, double blind, 3-arm, placebo-controlled, 
  multicenter, phase 3 trial to evaluate the safety and efficacy 
of oral cladribine vs placebo to prevent or delay conversion 
to definite MS (revised McDonald criteria)76 in patients with 
a first clinical demyelinating event at high risk of convert-
ing to MS. Subjects must have a minimum of 2 clinically 
silent lesions on the screening MRI. Depending upon the 
clinical course of their MS, subjects will proceed from the 
initial treatment period to an open-label IFNβ-period or, if 
no progression to MS has been noted after the initial treat-
ment period, to either open-label low-dose cladribine or no 
additional treatment. Estimated primary completion date is 
October 2012.
The safety and tolerability profile  
of cladribine
Parenteral cladribine has been in use for treatment of MS, 
hematological malignancies, and other indications for over 
15 years, providing a comparable established safety profile 
for the drug.73 However, safety data of oncology patients 
cannot directly be transferred to MS patients, as the   former 
population is often exposed to additional cytotoxic chemo-
therapy, and both populations are likely to differ in immune 
competence. Still, from indications other than MS, myelosup-
pression and infections have been noted. Escalating dose regi-
mens have been associated with, though typically transient, 
toxicity to stem cells. In particular, patients with poor bone 
marrow reserve experienced marked thrombocytopenia with 
repeated dosing.59,63 Toxicity seems to be dose-dependant and 
administration of cladribine at a dosage above the recom-
mended 0.1 mg/kg has been associated more frequently with 
myelosuppression, systemic infections, acute nephrotoxicity, 
and neuropathies. A significantly increased risk of   secondary 
malignancies has not been noted in patients treated with 
cladribine for lymphoma.68,77,78 For treatment of MS with 
parenteral cladribine, a combined analysis was performed 
using data from 268 patients enrolled in   Scripps-studies. 
Adverse events occurring most frequently in all groups 
were upper respiratory tract infections (32% cladribine 
group vs 24% placebo), headaches (28% cladribine group vs 
38% placebo), and injection-site reactions (24% cladribine 
group vs 25% placebo).79 The incidence of serious adverse 
events was similar in patients receiving cladribine at doses 
of 0.7–2.1 mg/kg or placebo (11–15% vs 17%).79 Although 
parenteral cladribine has shown to be teratogenic in mice 
and rabbits, there is no direct evidence for teratogenicity in 
humans.59 Nevertheless, this potential side effect needs to 
be taken into account.
Most valid data derive from the recently published 
oral CLARITY trial in MS population.46 As expected from 
  parenteral trials, lymphocytopenia (mostly graded as mild or 
moderate) is more frequently seen among patients   receiving 
cladribine compared with placebo. Severe neutropenia was 
reported in 3 patients (1 in the 3.5-mg group and 2 in the 
5.25-mg group). In 1 patient of the latter group, severe 
  thrombocytopenia and pancytopenia occurred, associated Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
123
Cladribine for MS
with an exacerbation of latent tuberculosis. Infections or 
infestations (graded mild or moderate in around 99% in 
all groups) were reported in 47.7% of the patients in the 
cladribine 3.5-mg group, 48.9% of those in the cladribine 
5.25-mg group, and 42.5% of those in the placebo group. 
Herpes zoster infections occurred in 20 cladribine-treated 
patients (8 patients in the 3.5-mg group and 12 in the 
5.25-mg group). All cases of herpes zoster were restricted 
to neighboring dermatomes, including 1 case of herpes 
zoster oticus. There were 3   uncomplicated cases of primary 
varicella, 1 in each study group. Adverse events leading to 
treatment discontinuation were seen in 3.5% of patients in 
the cladribine 3.5-mg group, 7.9% of those in the cladribine 
5.25-mg group, and 2.1% of those in the placebo group. 
The incidence of serious adverse events was 8.4% in the 
cladribine 3.5-mg group, 9.0% in the cladribine 5.25-mg 
group, and 6.4% in the placebo group. There were 3 cases 
of malignancies in the   cladribine 3.5-mg group (melanoma, 
pancreas carcinoma, and ovarian carcinoma). One case of 
cervical carcinoma in situ was also reported in the cladribine 
5.25-mg group in a human papillomavirus type 16 positive 
individual. A choriocarcinoma was diagnosed in 1 patient 
in the cladribine 5.25-mg group approximately 9 months 
after completion of the study. There were 4 deaths during 
the study and 2 after study discontinuation, equally distrib-
uted across the 3 study groups. Causes of death were acute 
myocardial infarction and metastatic pancreatic carcinoma 
in the cladribine 3.5-mg group, drowning and cardiopulmo-
nary arrest (considered secondary to exacerbation of latent 
tuberculosis) in the cladribine 5.25-mg group, and suicide 
and hemorrhagic stroke in the placebo group.
Perspective: potential of oral 
formulations in MS treatment  
with a focus on cladribine
The long-awaited publication of successful and well-
conducted phase 3 clinical trials of oral drugs for RRMS is 
promising news for more than 2 million people worldwide 
suffering from this chronic, disabling disease, as well as for 
their treating physicians. Among 5 currently investigated 
drugs at phase 3 clinical stage, efficacy and safety data for 
fingolimod (FTY720 Research Evaluating Effects of Daily 
Oral therapy in Multiple Sclerosis [FREEDOMS] and Trial 
Assessing Injectable IFN vs FTY720 Oral in   Relapsing 
Remitting Multiple Sclerosis [TRANSFORMS]) and 
cladribine (CLARITY) have been recently published.46–49 
From a patient’s perspective, the approval of oral therapies 
would definitely be appreciated, reducing restrictions on 
lifestyle and hope for more efficient treatment. Compared 
with other oral drugs, it is the only therapy with potential 
of short-course dosing. From the physician’s perspective, 
oral medication may promise improvement of treatment 
adherence. However, regarding the potential of drugs like 
cladribine, 3 key questions still need to be answered.
First, is cladribine treatment superior to currently 
  available drugs regarding efficacy? Only head-to-head   trials 
can give firm conclusion on the efficacy of cladribine vs 
established injectable therapies. These trials still need to 
be undertaken. Mainly due to the differences in severity of 
disease, comparing data across clinical trials is extremely 
problematic. Currently running studies are designed to 
evaluate cladribine as add-on to IFNβ and for early MS, 
but only comparative head-to-head trials will answer this 
question.
Second, do benefits exceed the risks in a long-term 
  perspective? We do not know by now, whether or not adverse 
effects seen in the recently published trials of cladribine 
and fingolimod are the only safety issues to consider. 
  Occurrence of herpes virus infections, as seen among patients 
  receiving cladribine or fingolimod, indicate an alteration of 
  endogenous viral immunosurveillance by these promising 
orals. In   addition, 3 cases of solid tissue cancers (pancreatic, 
ovarian, and melanoma) occurred among patients receiving 
cladribine. Keeping in mind the still unsolved and ongoing 
natalizumab-experience with occurrence of most relevant 
safety concerns in the postmarketing area,35–40 we cannot 
anticipate the long-term safety from the recently published 
phase 3 clinical trials. Particularly, with regard to rare oppor-
tunistic infections such as PML, only ongoing   extension 
trials such as the CLARTIY-Extension trial and, in case 
of approval, critical patient selection and high standards of 
postmarketing safety surveillance programs will enable us 
to estimate the risk and prevent harm.
Third, what would be the potential role of cladribine 
within established treatment concepts of RRMS? Similar to 
natalizumab, not efficacy data from phase 3 clinical trials, but 
safety data from still running trials and of a potential post-
marketing era, will finally answer this question. Cladribine, 
because of the known teratogenicity, should not be used in 
pregnancy, but also with caution in young female of potential 
child bearing capacity. In addition, as cladribine most likely 
alters viral immunosurveillance, it should not be used in com-
bination with other immunosupressives such as natalizumab 
or mitoxantrone, and even pretreatment with these agents 
could possibly put patients at higher risks. As efficacy data 
are strong and oral drugs are highly appreciated by most of Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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the patients, cladribine could potentially play a role in patients 
refractory to or patients not tolerating first-line treatment. In 
any case, individual decisions will be required and based on 
risk–benefit considerations in dialog with the well-informed 
patient, supported by high standards of postmarketing safety 
surveillance programs.
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